AbbVie secured global rights to ISB 2001, a first-in-class trispecific T-cell engager targeting BCMA, CD38, and CD3 for multiple myeloma, via an exclusive license deal with Ichnos Glenmark Innovation valued at over $1.9 billion. The Phase 1 TRIgnite-1 trial showed a 79% overall response rate, 30% complete responses, and 75% minimal residual disease negativity at active doses, with a favorable safety profile in heavily pretreated patients. AbbVie emphasized the potential of multispecific antibodies to deliver deeper and durable responses in difficult-to-treat cancers.